With 0.14 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.26 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.28 whereas the lowest price it dropped to was $2.21. The 52-week range on SEER shows that it touched its highest point at $2.62 and its lowest point at $1.51 during that stretch. It currently has a 1-year price target of $3.00. Beta for the stock currently stands at 1.59.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SEER was down-trending over the past week, with a drop of -6.36%, but this was down by -9.05% over a month. Three-month performance surged to 29.24% while six-month performance rose 32.34%. The stock gained 21.43% in the past year, while it has gained 13.92% so far this year. A look at the trailing 12-month EPS for SEER yields -1.30 with Next year EPS estimates of -1.57. For the next quarter, that number is -0.37. This implies an EPS growth rate of -2.96% for this year and -12.95% for next year. EPS is expected to decline by -11.70% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -67.17%.
Float and Shares Shorts:
At present, 55.54 million SEER shares are outstanding with a float of 37.36 million shares on hand for trading. On 2024-11-29, short shares totaled 1.29 million, which was 218.00000000000003 higher than short shares on 1730332800. In addition to Dr. Omid C. Farokhzad M.D., Ph.D. as the firm’s Founder, CEO, & Chair of the Board of Directors, Mr. David R. Horn serves as its President,Treasurer & CFO.
Institutional Ownership:
Through their ownership of 0.63751 of SEER’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, SEER reported revenue of $3942000.0 and operating income of -$24325000.0. The EBITDA in the recently reported quarter was -$22753000.0 and diluted EPS was -$0.35.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SEER since 1 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SEER analysts setting a high price target of 3.0 and a low target of 3.0, the average target price over the next 12 months is 3.0. Based on these targets, SEER could surge 35.75% to reach the target high and rise by 35.75% to reach the target low. Reaching the average price target will result in a growth of 35.75% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.38021 being high and -$1.39979 being low. For SEER, this leads to a yearly average estimate of -$1.39. Based on analyst estimates, the high estimate for the next quarter is -$0.33 and the low estimate is -$0.35. The average estimate for the next quarter is thus -$0.34.
